Literature DB >> 23213096

Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?

Nadeem Riaz, Eric J Sherman, Matthew Fury, Nancy Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23213096     DOI： 10.1200/JCO.2012.46.9049

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis.

Authors:  Caitriona B O'Neill; Shrujal S Baxi; Coral L Atoria; James P O'Neill; Martin C Henman; Eric J Sherman; Nancy Y Lee; David G Pfister; Elena B Elkin
Journal:  Cancer       Date:  2015-02-27       Impact factor: 6.860

Review 2.  Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Authors:  Neil Gildener-Leapman; Robert L Ferris; Julie E Bauman
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

3.  Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open question.

Authors:  Jacopo Giuliani; Andrea Bonetti
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-25       Impact factor: 2.503

4.  Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.

Authors:  Petar Suton; Marko Skelin; Zoran Rakusic; Stjepan Dokuzovic; Ivica Luksic
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-18       Impact factor: 2.503

5.  Unraveling the molecular genetics of head and neck cancer through genome-wide approaches.

Authors:  Nadeem Riaz; Luc G Morris; William Lee; Timothy A Chan
Journal:  Genes Dis       Date:  2014-09

6.  Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis.

Authors:  Jia Shen; Changling Sun; Min Zhou; Zhen Zhang
Journal:  Onco Targets Ther       Date:  2019-04-03       Impact factor: 4.147

7.  Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).

Authors:  M G Fury; E J Sherman; S S Rao; S Wolden; S Smith-Marrone; B Mueller; K K Ng; P R Dutta; D Y Gelblum; J L Lee; R Shen; S Kurz; N Katabi; S Haque; N Y Lee; D G Pfister
Journal:  Ann Oncol       Date:  2014-02-03       Impact factor: 32.976

8.  A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.

Authors:  Lara A Dunn; Nadeem Riaz; Matthew G Fury; Sean M McBride; Loren Michel; Nancy Y Lee; Eric J Sherman; Shrujal S Baxi; Sofia S Haque; Nora Katabi; Richard J Wong; Han Xiao; Alan L Ho; David G Pfister
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-10-31       Impact factor: 8.013
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.